Pyogenic vertebral osteomyelitis of the elderly: Characteristics and outcomes

PLoS One. 2017 Dec 5;12(12):e0188470. doi: 10.1371/journal.pone.0188470. eCollection 2017.

Abstract

Background: The incidence of pyogenic vertebral osteomyelitis (PVO) has increased over the past two decades. One possible cause of this increase is the aging of the population, which results in more comorbidities in high income countries.

Objective: To better characterize the clinical presentation and outcome of PVO in the elderly.

Design: We conducted a post-hoc analysis of a previously published trial that studied treatment duration in PVO and compared the presentation and outcomes according to age.

Participants: Our analysis included 351 patients among whom 85 (24%) were 75-years-old or more.

Results: There were no significant differences in the socio-demographics of the patients. Neoplasia and chronic inflammatory diseases were more common in the older group: 34% vs. 19% (p = 0.021) and 9% versus 1% (p = 0.004), respectively. There were no significant differences in clinical and radiological presentations between the groups in terms of back pain (337/351, 97%), fever (182/351, 52%), PVO localization, neurological signs and epidural abscess. Associated infective endocarditis (IE) was more frequent in the older group (37% vs. 14%, p<0.001). Streptococci were more frequently involved in infections of older patients (29% vs. 14%, p = 0.003) in contrast to Staphylococcus aureus (31% vs. 45%, p = 0.03). Older patients displayed higher mortality rates at 1 year (21% vs. 3%, p<0.001) and more adverse events related to cardiorespiratory failure (10.6% vs. 3.8%, p = 0.025), but had similar quality of life among the survivors.

Conclusion: During PVO, the clinical and radiological findings are similar in older patients. Global mortality rates are higher in older patients compared to younger patients, which could be explained by the increased frequency of neoplasia at diagnosis and higher prevalence of associated IE in the elderly.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Osteomyelitis / complications
  • Osteomyelitis / drug therapy
  • Osteomyelitis / pathology*
  • Spinal Diseases / complications
  • Spinal Diseases / pathology*
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / microbiology
  • Staphylococcal Infections / pathology*
  • Staphylococcus aureus / isolation & purification*
  • Treatment Outcome

Grants and funding

The DTS trial was funded by French Ministry of Health through a national Hospital Program for Clinical Research to Louis Bernard. The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.